IMPORTANCE Elevated fibroblast growth factor 23 (FGF-23) concentrations are associated with myocardial fibrosis and renin-angiotensin system upregulation, potentially providing prognostic information distinct from standard cardiovascular (CV) biomarkers.
F ibroblast growth factor 23 (FGF-23) is a protein hormone that was first described for its role in mineral metabolism. 1 Produced most abundantly by osteocytes, FGF-23 prevents reabsorption of phosphate in the renal proximal convoluted tubule and inhibits conversion of 25-hydroxyvitamin D to its active form. 1, 2 These effects limit hyperphosphatemia in renal failure, a disease associated with elevated concentrations of FGF-23. 1,2 Prior work has suggested a possible causal link between FGF-23 and adverse cardiovascular (CV) remodeling, in particular to the development of left ventricular hypertrophy, 3-5 alterations in myocyte calcium handling, 6 renin-angiotensin system upregulation, 7 and promotion of vascular calcification.
8
Given these pleotropic effects on CV structure and function, FGF-23 might be expected to provide prognostic value independent of established biomarkers. Previous observations have found elevated FGF-23 concentrations to be associated with adverse CV outcomes in patients without established CV disease [9] [10] [11] [12] [13] [14] [15] and in patients with stable coronary artery disease and preserved left ventricular ejection fraction.
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The prognostic utility of FGF-23 in patients stabilized after a recent acute coronary syndrome (ACS) remains unknown, however. We therefore examined the association of FGF-23 with recurrent CV events in patients after ACS in the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial. 17 
Methods

Study Design and Participants
The study design, baseline patient characteristics, and primary results of the SOLID-TIMI 52 trial (NCT01000727) 18 have been previously described. 17, 19 In brief, SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial performed from December 1, 2009 , to April 24, 2014 , that randomized 13 026 patients within 30 days of ACS (median, 14 days) to the lipoprotein-associated phospholipase A 2 inhibitor darapladib or placebo, with a median follow-up of 2.5 years. In addition to the recent ACS, patients were required to have 1 additional CV risk factor for inclusion in the trial. Major exclusion criteria relevant to the current analysis included coronary artery bypass graft surgery completed or planned for the index ACS, liver disease, estimated glomerular filtration rate (eGFR) less than 30 mL/min/ 1.73 m 2 by the Modification of Diet in Renal Dysfunction formula, New York Heart Association class III or IV heart failure, poorly controlled hypertension, and life expectancy less than 2 years because of a non-CV condition. Written informed consent was provided by all participants, and the study protocol was approved by all relevant institutional review boards (see the full list of all participating institutions in SOLID-TIMI 52 in eAppendix 1 in Supplement 1 in the report by O'Donoghue et al 17 )
. The SOLID-TIMI 52 trial and this post hoc secondary analysis (performed from September 25, 2014 , to October 1, 2017 comply with the Declaration of Helsinki. 20 All data were deidentified.
End Points
On the basis of prior work 16 showing the prognostic value of an elevated FGF-23 concentration for CV death or heart failure hospitalization but not atherothrombotic events in patients with stable ischemic heart disease, the primary prespecified outcome of interest for the current analysis was the composite of CV death or heart failure hospitalization. Other end points captured in the SOLID-TIMI 52 trial were also examined, including the primary trial end point of major coronary events (coronary heart disease death, myocardial infarction [MI], or urgent revascularization for myocardial ischemia) and the key secondary end point of major adverse CV events (MACE), defined as CV death, MI, or stroke. All deaths, heart failure hospitalizations, cardiac ischemic events, and cerebrovascular events were adjudicated by an independent and blinded clinical events committee according to prespecified criteria. 17, 19 Atrial fibrillation was captured as a term in the safety database but was not adjudicated.
Measurement of Biomarkers
The FGF-23 concentrations were analyzed at baseline in 4947 patients randomly selected from the overall trial cohort. Patients included in the biomarker subgroup had baseline characteristics similar to the overall trial population (eTable 1 in the Supplement). The FGF-23 concentration was measured in duplicate using a C-terminal human enzyme-linked immunosorbent assay (Immutopics) 21 with a median coefficient of variation of 3.86% (eTable 2 in the Supplement). Mean (SD) normal values for this assay in adults with preserved renal function were 55 (50) reference units (RU)/mL. 21 All assays for FGF-23
and other biomarkers, including high-sensitivity troponin I (hsTnI) (Architect i2000SR, Abbott Laboratories), highsensitivity C-reactive protein (hsCRP) (cobas 6000, Roche Diagnostics), brain-type natriuretic peptide (BNP) (Architect i2000SR, Abbott Laboratories), and cystatin-C (Randox), were performed in the TIMI Clinical Trials Laboratory (Boston, Massachusetts) by laboratory personnel masked to treatment allocation and clinical outcome.
Key Points
Question Is fibroblast growth factor 23 associated with recurrent cardiovascular events in patients stabilized after an acute coronary syndrome?
Findings Among 4947 patients with recent acute coronary syndrome enrolled in the SOLID-TIMI 52 trial, fibroblast growth factor 23 was independently and significantly associated with an increased risk of cardiovascular death or heart failure hospitalization and its individual components after adjustment for baseline clinical characteristics and established biomarkers (high-sensitivity troponin I, brain-type natriuretic peptide, and high-sensitivity C-reactive protein). Although this association was robust in men, C-terminal fibroblast growth factor 23 did not appear to be useful for risk stratification in women.
Meaning In patients stabilized after acute coronary syndrome, elevated fibroblast growth factor 23 concentrations may be associated with recurrent major cardiovascular events independent of established clinical risk factors and cardiorenal biomarkers; however, this association may be attenuated in women. Cumulative rates of all outcomes and their components were calculated for each quartile using the Kaplan-Meier method reported at 3 years and tested for significance with the trend test. The association between FGF-23 concentration and trial end points was examined using Cox proportional hazards regression models to produce hazard ratios (HRs) and 95% CIs for elevation in FGF-23 concentrations, which were analyzed as categorical and continuous variables (as restricted cubic splines). Clinical risk predictors were included in the risk adjustment model (age, sex, body mass index [BMI] , current smoker, race/ethnicity [white vs nonwhite], geographic region, hypertension, hyperlipidemia, diabetes, MI before qualifying event, index diagnosis, days from qualifying event, baseline low-density lipoprotein cholesterol concentration, and randomized treatment arm), in addition to eGFR (Modification of Diet in Renal Dysfunction formula), cystatin-C, hsTnI, hsCRP, and BNP measurements. On the basis of inspection of the distribution of continuous variables, the following variables were log-transformed: BMI, low-density lipoprotein cholesterol, cystatin-C, hsTnI, hsCRP, BNP, and FGF-23. Additional restricted cubic splines were used for age and biomarker data (hsTnI, hsCRP, and BNP) in which nonlinear associations were still significant after transformation. Cystatin-C and eGFR were highly correlated (Spearman correlation coefficient r = −0.68) with each other; thus, only eGFR was retained in the final model.
Statistical Analysis
We also explored the FGF-23 cut point for CV death or heart failure by the Youden index in the context of receiver operating curve analysis because descriptive data showed evidence of a threshold effect. 22 We observed that an FGF-23 concentration of 92.8 RU/mL was an optimal cutoff value that maximized discrimination between those who had a clinical event (CV death or heart failure hospitalization) and those who did not, and this value was close to the third quartile of FGF-23 distribution (93.5 RU/mL). On the basis of an apparent threshold in risk between the third and fourth quartiles, categorical FGF-23 data were further analyzed as a binary variable (quartile 4 vs quartiles 1-3). There was no interaction by treatment arm, and all analyses were therefore performed in the full biomarker subgroup (n = 4947). Metrics of discrimination (C-statistic, categoryless net reclassification improvement, and integrated discrimination improvement) were calculated for the adjusted multivariable models with and without Table 1 ). The FGF-23 concentrations were moderately correlated with eGFR (r = −0.29) and cystatin-C (r = 0.39) and weakly with hsTnI (r = 0.05), hsCRP (r = 0.14), and BNP (r = 0.20) (eTable 3 in the Supplement).
Unadjusted Risk of CV Outcomes
During a median follow-up period of 2.5 years, 205 CV deaths and 183 hospitalizations for heart failure occurred. There were 648 MACE, including 404 fatal or nonfatal MIs and 118 fatal or nonfatal strokes.
When FGF-23 was modeled as a continuous variable, there was a significant 75% higher risk of CV death or heart failure hospitalization for each SD increase in log-transformed FGF-23 (HR, 1.75; 95% CI, 1.61-1.91; P < .001). A similar higher risk was observed for each of the individual components of the composite end point and MACE.
When the FGF-23 concentrations were categorized by quartile, patients with higher baseline FGF-23 concentrations had a significant increase in the 3-year rate of CV death or heart failure hospitalization with evidence of an apparent threshold effect between quartiles 3 and 4 (4.4% in quartile 1, 4.7% in quartile 2, 4.9% in quartile 3, and 17.5% in quartile 4; P < .001) (eTable 4 and eFigures 1 and 2 in the Supplement). Similar observations were seen for the rates of all-cause mortality, with a marked inflection in risk for patients with FGF-23 concentrations between the third and fourth quartiles (5.0% in quartile 1, 5.2% in quartile 2, 4.3% in quartile 3, and 14.6% in quartile 4; P < .001) (eTable 4 in the Supplement). As such, subsequent analyses modeled FGF-23 as a dichotomous variable by applying a threshold of quartile 4 vs quartiles 1 through 3. The observed risk of CV death or heart failure and MACE for patients with FGF-23 concentrations in the top quartile emerged early and persisted over time ( Figure 1 and eFigure 3 in the Supplement).
Adjusted Risk of CV Outcomes
After multivariable adjustment for the clinical characteristics and the renal and CV biomarkers previously described, patients with FGF-23 concentrations in quartile 4 had more than a 2-fold higher risk of CV death or heart failure hospitalization than patients with FGF-23 concentrations in quartiles 1 through 3 (adjusted HR, 2.35; 95% CI, 1.82-3.02; P < .001), including increased risks of CV death and heart failure hospitalization individually (Figure 2 ). The FGF-23 concentrations in quartile 4 were also associated with an increased risk of allcause mortality, CV death, MI or stroke, fatal or nonfatal stroke, and atrial fibrillation ( Figure 2 ). The association with MI was directionally consistent but of lesser magnitude.
Inclusion of baseline left ventricular ejection fraction (available in 4163 patients) in the multivariable model yielded simi- lar findings (CV death or heart failure: adjusted HR, 2.39; 95% CI, 1.81-3.15; P < .001 for quartile 4 vs quartiles 1-3). Furthermore, FGF-23 provided an incremental value for risk stratification when analyses were stratified by baseline eGFR (≤60 or >60 mL/min/1.73 m 2 ) (eFigure 4 in the Supplement). In the described risk model including clinical variables, established biomarkers, eGFR, and FGF-23, the adjusted HR for CV death or heart failure hospitalization was 1.51 (95% CI, 1.18-1.93) for low eGFR (≤60 mL/min/1.73 m 2 ) and 2.44 (95% CI, 1.92-3.09) for elevated FGF-23 concentration (quartile 4). When dividing patients into 4 groups with high eGFR (>60 mL/min/1.73 m 2 ) and low FGF-23 concentration (quartiles 1-3) as the reference, the adjusted HR of CV death or heart failure hospitalization was 1.56 (95% CI, 1.07-2.27) for patients with low eGFR and low FGF-23 concentration, 2.61 (95% CI, 1.95-3.50) for patients with high eGFR and high FGF-23 concentration, and 2.88 (95% CI, 2.10-3.95) for patients with the highest-risk combination of low eGFR and high FGF-23 concentration ( Figure 3A and Figure 3B and Table 2 ).
Discrimination and Reclassification
Compared with the base model of clinical variables, inclusion of FGF-23 (restricted cubic spline) significantly improved the model for risk of CV death or heart failure hospitalization (likelihood ratio test P < . Biomarker stratifications are as follows: for fibroblast growth factor 23 (FGF-23) and brain-type natriuretic peptide (BNP), quartile 4 was high and quartiles 1 through 3 were low; for estimated glomerular filtration rate (eGFR), greater than 60 mL/min/1.73 m 2 was high and 60 mL/min/1.73 m 2 or less was low; and for high-sensitivity troponin I (hsTnI), quartiles 2 through 4 were high and quartile 1 was low. 
Interaction by Sex
Discussion
In a large, contemporary cohort of patients with recent ACS, we found that an elevated FGF-23 concentration was associated with the risk of adverse CV outcomes, including CV death or heart failure hospitalization. Furthermore, FGF-23, a protein reflective of physiologic axes separate from those affecting traditional CV biomarkers, provided prognostic information that was incremental to established clinical predictors and multiple biomarkers, including eGFR, BNP, hsCRP, and hsTnI. To our knowledge, this is the first time this association has been explored in patients stabilized after recent ACS. An apparent attenuation of this association in women additionally merits further investigation. The median FGF-23 concentration of 63.1 RU/mL (IQR, 46.0-93.5 RU/mL) observed here is similar to that seen in patients with stable ischemic heart disease (50.6 RU/mL; IQR, 38.7-69.9 RU/mL) 16 but higher than concentrations in the general population 9,24 and lower than those in patients with chronic kidney disease.
3,4
The observed correlation between FGF-23 concentration and subsequent CV risk after ACS is intriguing with respect to the protein's postulated direct and indirect CV effects. In non-ACS populations, an elevated FGF-23 concentration has been associated with mortality and heart failure but with mixed associations with atherothrombotic outcomes. [9] [10] [11] 16, [25] [26] [27] In the current analysis, we observed an association between FGF-23 and the risk of CV death, heart failure hospitalization, and allcause mortality among patients after ACS. However, we also found an independent association between FGF-23 concentration and the risk of MACE with directional consistency across all components.
Pathophysiologic and Clinical Considerations
The renin-angiotensin system is a central mediator of the CV effects of FGF-23. Klotho, the FGF-23 coreceptor in the kidney and vasculature, is a renin-angiotensin system inhibitor, [28] [29] [30] However, a study 9 in patients did not find consistent associations between FGF-23 and vascular events. Our results in a post-ACS population show an independent association between FGF-23 and the risk of subsequent stroke and a weaker association with MI. The Multi-Ethnic Study of Atherosclerosis (MESA) found an elevated FGF-23 concentration to be associated with incident coronary heart disease events in the general population, 32 whereas other nontrial cohorts of lower-risk patients did not find statistically significant associations between increased stroke and/or MI. 9 In a cohort of patients enrolled 6 to 12 months after ACS, elevated FGF-23 concentration was associated with higher incidence of a composite outcome, including ischemic events, heart failure, and allcause mortality.
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The statistically significant interaction with patient sex was unexpected. Higher concentrations of FGF-23 in women compared with men have been reported in observational cohorts irrespective of FGF-23 assay used, 11,16 although differential prognostic value of this biomarker in women has not previously been shown. Estrogen is known to influence concentrations of FGF-23-modifying compounds, including parathyroid hormone, phosphate, and vitamin D, 24 and may contribute to an observed sex difference in the association between serum phosphorus concentration and CV outcomes. Abbreviations: BNP, brain-type natriuretic peptide; eGFR, estimated glomerular filtration rate; FGF-23, fibroblast growth factor 23; HR, hazard ratio; hsTnI, high-sensitivity troponin I.
a Biomarker stratifications are as follows: for FGF-23 and BNP, quartile 4 was high and quartiles 1 through 3 were low; for eGFR, greater than 60 mL/ min/1.73 m 2 was high and 60 mL/min/1.73 m 2 or less was low; and for hsTnI, quartiles 2 through 4 were high and quartile 1 was low.
Because the current study enrolled patients after ACS, most women were likely to have been postmenopausal. Menopause results in urine phosphorus retention, which in turn is believed to increase FGF-23 concentration. 40 In fact, postmenopausal women not receiving exogenous estrogen have higher FGF-23 concentrations than postmenopausal women receiving estrogen therapy or men. 40 Conceivably, low FGF-23 concentrations in this context may reflect intrinsically low FGF-23 concentrations or low FGF-23 concentrations related to exogenous estrogen. One cannot exclude that the observed difference by patient sex could have occurred by chance. Of note, the prognostic utility of FGF-23 previously appeared to be broadly comparable in men and women in the Atherosclerosis Risk in Communities (ARIC) study and MESA.
11,32 However, the current study measured the C-terminal fragment of FGF-23 as opposed to the intact peptide that was previously measured in the older studies. As such, it remains unclear whether the observed findings may reflect differences between men and women in the posttranslational processing of FGF-23. Further study will be useful in that regard.
Limitations
Although the present analysis benefits from a wellcharacterized trial cohort, a large sample size and number of events, and adjudicated outcomes, it has several limitations. First, the analysis is observational and does not allow for causal inference. Second, left ventricular ejection fraction was only assessed in 84% of patients; however, the findings remained consistent after inclusion of left ventricular ejection fraction in the adjustment model. Finally, any clinical cut points for FGF-23 will require prospective validation in a separate cohort in addition to validation of the observed interaction by patient sex.
Conclusions
In a large, contemporary cohort of patients with recent ACS, we found elevated FGF-23 concentrations to be associated with a higher risk of adverse CV outcomes independent of established risk predictors and cardiorenal markers. A potential sex difference in these findings deserves further study.
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